Tweets
The Efficacy of Ianalumab in Sjögren’s Disease
The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or https://t.co/YStzIFq5Bx
Dr. John Cush @RheumNow ( View Tweet )
2 hours 1 minute ago
Tx persistence & response in PsA is a problem - influenced by demographics & Dz severity. 815 PsA pts in e Brit Society Rheumatology PsA Registe. @12 mos - 24% MDA, 24% ACR50. Median F/U 31 mos, only 65% still on index Rx. D/C higher w/ PDE4i & poorer baseline activity & PROs https://t.co/BhxAMtjsZV
Dr. John Cush @RheumNow ( View Tweet )
3 hours 32 minutes ago
🚨NOW IN THE POSTER HALL: Long-Term Safety of a JAKi in Clinical Trial and Real-World Settings Across >21,000 Patient-Years
Check out the data in RA, PsA, AS, and nr-axSpA presented at EULAR 2026: https://t.co/QdAKpL3Vjv
Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/VYBvGp7Wnd
Dr. John Cush @RheumNow ( View Tweet )
4 hours 58 minutes ago
Patients with type 2 SLE present with fatigue, pain, brain fog and mood changes.
Type 1 & 2 often coexist but type 2 SLE impacts QOL.
@RheumNow #lupus #APLAR2026 https://t.co/aMtoIprPWG
sheila @RHEUMarampa ( View Tweet )
15 hours 28 minutes ago
Excites to report on #APLAR26 in Seoul, S. Korea for @RheumNow along with Drs. @RHEUMarampa and Peter Nash https://t.co/QImSxM7Izi
Jiha Lee @JihaRheum ( View Tweet )
15 hours 29 minutes ago
24-Week Interim Findings from a Randomized Phase 2 Study of Iptacopan (LNP023) Indicate High Remission Rates in Participants with Active ANCA-Associated Vasculitis https://t.co/cUNMo2ngeE and liver safety over time is?
Peter Nash @drpnash ( View Tweet )
15 hours 31 minutes ago
CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Associated T Cells in Axial Spondyloarthritis https://t.co/RPD7FkgEdQ anti-TRVB and anti-TRAV for your B27 AxSpA patients ( and needs looking at B27 positive PsA ) watch this space
Peter Nash @drpnash ( View Tweet )
15 hours 31 minutes ago
Schett : in vivo the future if it works, during LD aciclovir, co-trimoxazole, CAR-T expansion amount not associated with toxicity, 3 month no vaccination window, all tissues B cell depletion , naive b cells return
APLAR Seoul 2026 #CART #RheumNow
Peter Nash @drpnash ( View Tweet )
15 hours 31 minutes ago
number of naive-like CAR-T infused associates with prolonged survival but highly variable
APLAR Seoul 2026 #CAR-T #Rheum Now
Peter Nash @drpnash ( View Tweet )
15 hours 32 minutes ago
Chan Hong Kong prediction CRS
80/20 - 80% CRS 20% hypoxia hypotension etc predictors 4 groups b cell load and IL6 level
APLAR Seoul 2026 #CART #RheumNow https://t.co/Q3C9RaYPFz
Peter Nash @drpnash ( View Tweet )
15 hours 32 minutes ago
Georg Schett : cure prime goal of therapy! remission off all treatment ,
APLAR Seoul 2026 #CART #RheumNow https://t.co/kygOGdxUSe
Peter Nash @drpnash ( View Tweet )
15 hours 32 minutes ago
lymphodepletion depends on individual cytokine profile and fludarabine PK effects efficacy
APLAR Seoul 2026 #CAR-T #Rheum Now
Peter Nash @drpnash ( View Tweet )
15 hours 34 minutes ago
Raff - Creative - lipid nanoparticle delivery
APLAR Seoul 2026 #CART #RheumNow https://t.co/1O11I5pR8P
Peter Nash @drpnash ( View Tweet )
15 hours 34 minutes ago
“Complex to manage” in SLE not for biologics
APLAR Seoul 2026 Nikpour #SLE #RheumNow https://t.co/4qeRGEVijs
Peter Nash @drpnash ( View Tweet )
15 hours 34 minutes ago
ExVivo advantages
APLAR Seoul 2026 #CART #RheumNow https://t.co/db2jIVDaik
Peter Nash @drpnash ( View Tweet )
15 hours ago
